GSK plc (NYSE:GSK) is one of the 12 best healthcare stocks to buy now. On June 12, the company announced licensing its Shigella vaccine candidate to Bharat Biotech. The licensing is part of the ...

GSK plc (NYSE:GSK) is one of the 12 best healthcare stocks to buy now. On June 12, the company announced licensing its Shigella vaccine candidate to Bharat Biotech.

Hyderabad-based Bharat Biotech has partnered with GSK—a British multinational pharmaceutical and biotechnology company—for the ongoing development and potential use of the Shigella vaccine ...

Hyderabad: Vaccine maker Bharat Biotech International Limited (BBIL) has in-licensed pharma giant GSK's under development Shigella vaccine candidate, .

Bharat Biotech has in-licensed GSK's Shigella vaccine candidate, altSonflex1-2-3, aimed at combating Shigellosis in young children in low- and middle-income countries.

Bharat Biotech and GSK collaborate to advance Shigella vaccine, aiming to combat urgent public health threat globally.

After the shigella technology transfer, GSK will work with Bharat to design the phase 3 trial and support its partner’s search for external funding.

Bharat Biotech joins GSK to develop a Shigella vaccine to fight shigellosis in children, with Phase 3 trials underway and focus on low-income countries.

A 2024 shigella outbreak killed five Jacksonville Zoo apes. What you should know about the highly contagious illness that can affect humans, too.

A traveller’s persistent diarrhoea uncovers a surprising dual infection. Explore why detailed history and diagnostics are critical in such cases.

The county has reported 18 Shigella infections so far this year, as of Thursday. That's already higher than the case count for all of last year, which was 12.

Valneva intends to test its experimental Shigella vaccine in nearly 110 infants. Results from this study are expected later this year.